---
title: "W Health Ventures Fund II: ~$80M Final Close at ₹700 Cr for Company Creation"
description: "W Health Ventures closed Fund II at ₹700 crore (~$80M), above its ₹630 Cr target — a physician-operator company-creation vehicle already launching Everhope Oncology and Everbright Health."
date: 2026-09-08T00:00:00.000Z
tags: ["2026-vc-news", "fund-news", "venture-capital", "healthtech", "india-vc", "company-creation"]
source: https://venturecapitaltracker.com/2026-w-health-ventures-fund-ii-700-cr-final-close
---

# W Health Ventures Fund II: ~$80M Final Close at ₹700 Cr for Company Creation

> W Health Ventures closed Fund II at ₹700 crore (~$80M), above its ₹630 Cr target — a physician-operator company-creation vehicle already launching Everhope Oncology and Everbright Health.

**W Health Ventures** closed **Fund II at ₹700 crore (~US$80 million)** — above its **₹630 crore** target — according to **September 8, 2026** coverage (**Indian Startup Times**). That follows a **February 2026 ₹550 crore** first close (**Economic Times**).

**Spine:** this is a **company-creation** vehicle, not a classic spray-and-pray seed fund — physicians and operators incubate the thesis before a founding team is hired.

## Key facts

| Field | Detail |
| --- | --- |
| Firm | W Health Ventures (Mumbai, Bengaluru, Delhi, Boston) |
| Fund | Fund II final close **₹700 Cr (~$80M)** |
| Prior milestone | First close **₹550 Cr** (Feb 2026); target was **₹630 Cr** |
| Model | 12–18 months internal de-risking → founding team |
| Pace plan | **8–10** companies / four years; **₹30–50 Cr** per incubation; **2–3**/year |
| Fund II launches cited | **Everhope Oncology** (with Narayana Health); **Everbright Health** (US TRD clinics) |
| Firm claim | Portfolio companies reached **25M** patients to date |

## Who this capital serves

**Patients/providers:** new category companies in oncology, psychiatry, chronic care, and related gaps where WHV believes first-mover coordinated care beats incremental clinic SaaS.

**Founding CEOs:** operators plugged into a pre-diligence thesis rather than a blank-sheet seed.

**LPs:** healthcare specialists who want India + US-India corridor exposure with operational involvement baked in.

## Why now

- India healthcare demand is scaling faster than coordinated specialty capacity (oncology, obesity, mental health).
- Cross-border US-India psychiatry/oncology plays need patient capital that can wait through incubation.
- Completing above target after a February first close suggests LP demand for **builder funds** outpaced the original ₹630 Cr ask.

## What is not proven

- LP roster and management fees were **not detailed** in the IST piece.
- “25 million patients” is a **firm claim** across the portfolio, not Fund II alone.
- FX on **~$80M** is illustrative (~₹87.5/$); lead with **₹700 Cr** as the disclosed close figure.

## Implication

WHV’s scoreboard is **companies launched and clinical outcomes**, not deal count. Watch whether Everhope and Everbright raise external growth capital on schedule — that is how Fund I was validated.

### Sources

1. [Indian Startup Times — ₹700 Cr close](https://www.indianstartuptimes.com/investment/w-health-ventures-closes-second-fund-at-rs-700-crore-to-build-healthcare-companies/)
2. [Economic Times — ₹550 Cr first close](https://m.economictimes.com/tech/funding/w-health-ventures-announces-first-close-of-second-fund-at-rs-550-crore-to-back-8-10-healthcare-startups/amp_articleshow/128219156.cms)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.